BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-15 out of 15 found
  Current Search:  sturge: 15, weber: 69     

HTML
54%
OctoPlus' licensee Biolex completes patient enrollment in Phase IIb study with Locteron
-OctoPlus N.V.

('OctoPlus') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron,...

Pharma Live:  Jul 2 2009 10:41AM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus appoints Susan Swarte as Chief Financial Officer
- OctoPlus N.V.

announced that Susan Swarte will join the Company on 1 August as Chief Financial Officer.

At the next general meeting of shareholders the Board of Supervisory Directors will propose to appoint Mrs.

Swarte as member of...

Bionity.com:  Jun 30 2009 4:47AM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus appoints Susan Swarte as Chief Financial Officer
- OctoPlus N.V.

('OctoPlus' or the 'Company') (Euronext: OCTO), the drug delivery company, announces today that Susan Swarte will join the Company on 1 August as Chief Financial Officer.

At the next general meeting of shareholders the...

BioSpace:  Jun 29 2009 5:58PM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus appoints Susan Swarte as Chief Financial Officer
OctoPlus N.V.

('OctoPlus' or the 'Company') (Euronext: OCTO), the drug delivery company, announces today that Susan Swarte will join the Company on 1 August as Chief Financial Officer.

At the next general meeting of shareholders the...

Genetic Engineering News:  Jun 29 2009 6:17AM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus' Licensee Biolex Therapeutics Completes Patient Enrollment in Phase IIb Study With Locteron
- OctoPlus N.V.

('OctoPlus') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron...

BioSpace:  Jun 29 2009 5:58PM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus N.V. (NL) - OctoPlus opens new GMP manufacturing facility
-OctoPlus N.V.

('OctoPlus' or the 'Company') (Euronext: OCTO) announces today that it has started pharmaceutical production in its new manufacturing facility in Leiden.

The facility has received a license from the Dutch authorities to...

Pharma Live:  Jun 25 2009 7:43PM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus Opens New GMP Manufacturing Facility
- OctoPlus N.V.

('OctoPlus' or the 'Company') (Euronext: OCTO) announces today that it has started pharmaceutical production in its new manufacturing facility in Leiden.

The facility has received a license from the Dutch authorities to...

BioSpace:  Jun 23 2009 5:37PM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus Opens New GMP Manufacturing Facility
OctoPlus N.V.

('OctoPlus' or the 'Company') (Euronext: OCTO) announces today that it has started pharmaceutical production in its new manufacturing facility in Leiden.

The facility has received a license from the Dutch authorities to...

Genetic Engineering News:  Jun 23 2009 6:48AM
Matching: sturge
Find similar documents
HTML
100%
Study: Ahmed valve survival rate at 63% in patients younger than 2 years
Submit a Comment Patients under the age of 2 years who received an Ahmed valve implantation had a cumulative valve survival rate of more than 60%, with postoperative tube malpositioning the most common postop complication, according to a...
OSN Super Site:  Jun 10 2009 10:56PM
Matching: sturge weber
Find similar documents
HTML
100%
Study: Ahmed valve survival rate at 63% in patients younger than 2 years
Br J Ophthalmol.

2009;93(6):795-798.

Patients under the age of 2 years who received an Ahmed valve implantation had a cumulative valve survival rate of more than 60%, with postoperative tube malpositioning the most common postop...

PCON SuperSite:  Jun 10 2009 9:29PM
Matching: sturge weber
Find similar documents
HTML
54%
OctoPlus N.V. (NL) - OctoPlus to present at two investor conferences in June
-OctoPlus N.V.

(Euronext: OCTO), the drug delivery company, announces today that its CEO will present at two investor conferences in Germany and the United Kingdom in June.

Simon Sturge, Chief Executive Officer, will present on...

Pharma Live:  Jun 4 2009 8:19PM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus to Present at Two Investor Conferences in June
- OctoPlus N.V.

(Euronext: OCTO), the drug delivery company, announces today that its CEO will present at two investor conferences in Germany and the United Kingdom in June.

Simon Sturge, Chief Executive Officer, will present on...

BioSpace:  Jun 2 2009 9:38PM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus to present at two investor conferences in June
OctoPlus N.V.

(Euronext: OCTO), the drug delivery company, announces today that its CEO will present at two investor conferences in Germany and the United Kingdom in June.

Simon Sturge, Chief Executive Officer, will present on...

Therapeutics Daily:  Jun 2 2009 10:20AM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus to Present at Two Investor Conferences in June
OctoPlus N.V.

(Euronext: OCTO), the drug delivery company, announces today that its CEO will present at two investor conferences in Germany and the United Kingdom in June.

Simon Sturge, Chief Executive Officer, will present on...

Genetic Engineering News:  Jun 2 2009 6:55AM
Matching: sturge
Find similar documents
HTML
54%
OctoPlus N.V. (NL) - OctoPlus' licensee Biolex commences Phase IIb study with Locteron
LEIDEN, The Netherlands -- OctoPlus N.V.

('OctoPlus' or 'the Company') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on In October 2008 OctoPlus entered into an exclusive license...

Pharma Live:  Apr 20 2009 7:33PM
Matching: sturge
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.